Inhibiting the p53-MDM2 interaction: an important target for cancer therapy (Q35058579)

6 August 2017

title

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy (English)

1 reference

6 August 2017

Patrick Chène

1

1 reference

6 August 2017

publication date

1 February 2003

1 reference

6 August 2017

language of work or name

English

0 references

published in

Nature Reviews Cancer

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

102-109

1 reference

publication type of scholarly work

6 August 2017

review article

1 reference

Regulation of the p53 tumor suppressor protein

cites work

1 reference

Live or let die: the cell's response to p53

21 January 2018

1 reference

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

P53: an ubiquitous target of anticancer drugs

21 January 2018

1 reference

21 January 2018

Targeting p53 in cancer

1 reference

The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?

21 January 2018

1 reference

The p53-mdm-2 autoregulatory feedback loop

21 January 2018

1 reference

Mapping of the p53 and mdm-2 Interaction Domains

21 January 2018

1 reference

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

21 January 2018

1 reference

Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

21 January 2018

1 reference

Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53

21 January 2018

1 reference

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

21 January 2018

1 reference

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

Regulation of p53 stability by Mdm2

21 January 2018

1 reference

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

21 January 2018

1 reference

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

21 January 2018

1 reference

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein

21 January 2018

1 reference

Molecular mechanism of the interaction between MDM2 and p53.

21 January 2018

1 reference

Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21.

21 January 2018

1 reference

Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding

21 January 2018

1 reference

DNA damage-induced activation of p53 by the checkpoint kinase Chk2

21 January 2018

1 reference

Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage

21 January 2018

1 reference

Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis

21 January 2018

1 reference

The MDM2 gene amplification database

21 January 2018

1 reference

Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors

21 January 2018

1 reference

Abnormal expression of MDM2 in prostate carcinoma

21 January 2018

1 reference

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

21 January 2018

1 reference

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein

21 January 2018

1 reference

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2

21 January 2018

1 reference

Solution conformation of an essential region of the p53 transactivation domain

21 January 2018

1 reference

Principles of protein-protein interactions

21 January 2018

1 reference

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

21 January 2018

1 reference

Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers

21 January 2018

1 reference

Alternative and aberrant splicing of MDM2 mRNA in human cancer

21 January 2018

1 reference

From p63 to p53 across p73.

21 January 2018

1 reference

The p53 and Mdm2 families in cancer.

21 January 2018

1 reference

P63 and P73: P53 mimics, menaces and more

21 January 2018

1 reference

Regulation of p63 function by Mdm2 and MdmX.

21 January 2018

1 reference

MDM2 and MDMX bind and stabilize the p53-related protein p73

21 January 2018

1 reference

Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence

21 January 2018

1 reference

MDM2 suppresses p73 function without promoting p73 degradation

21 January 2018

1 reference

Molecular characterization of the hdm2-p53 interaction

21 January 2018

1 reference

Aib-based peptide backbone as scaffolds for helical peptide mimics

21 January 2018

1 reference

Efficient electrostatic solvation model for protein-fragment docking

21 January 2018

1 reference

Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.

21 January 2018

1 reference

Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

21 January 2018

1 reference

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

21 January 2018

1 reference

p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.

21 January 2018

1 reference

Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells

21 January 2018

1 reference

Genetic determinants of p53-induced apoptosis and growth arrest

21 January 2018

1 reference

The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2.

21 January 2018

1 reference

Inhibition of protein-protein association by small molecules: approaches and progress

21 January 2018

1 reference

The MDM2 C-terminal Region Binds to TAFII250 and Is Required for MDM2 Regulation of the Cyclin A Promoter

21 January 2018

1 reference

The Mdm2 oncoprotein interacts with the cell fate regulator Numb

21 January 2018

1 reference

A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2

21 January 2018

1 reference

p19ARF links the tumour suppressor p53 to Ras

21 January 2018

1 reference

Tumor-suppressor p53: implications for tumor development and prognosis

21 January 2018

1 reference

mdm2 expression is induced by wild type p53 activity

31 March 2020

1 reference

Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length

31 March 2020

1 reference

Comparative study of the p53-mdm2 and p53-MDMX interfaces

31 March 2020

1 reference

Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53

31 March 2020

1 reference

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure

31 March 2020

1 reference

Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells

31 March 2020

1 reference

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC991

1 reference

6 August 2017

1 reference